Back to top
more

Editas Medicine (EDIT)

(Delayed Data from NSDQ)

$1.38 USD

1.38
2,458,301

-0.03 (-2.13%)

Updated Jan 24, 2025 04:00 PM ET

After-Market: $1.38 0.00 (0.00%) 7:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.30%
2Buy18.13%
3Hold9.74%
4Sell5.28%
5Strong Sell2.72%
S&P50011.39%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (78 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Balance Sheet

Research for EDIT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Editas Medicine, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Assets          
Cash & Equivalents -99,999 323 344 500 402
Receivables NA 10 5 0 6
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 8 7 7 11
Total Current Assets NA 341 357 507 419
Net Property & Equipment NA 12 16 17 14
Investments & Advances NA 104 93 120 110
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 9 5 7 5
Total Assets NA 499 514 677 573
Liabilities & Shareholders Equity 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Notes Payable NA 0 0 0 0
Accounts Payable NA 8 10 5 6
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 35 31 20 24
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 8 8 11 21
Total Current Liabilities NA 63 60 47 58
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 61 61 61 74
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 2 0 0 28
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 150 154 124 179
Shareholders Equity 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,580 1,442 1,412 1,059
Retained Earnings NA -1,231 -1,078 -858 -665
Other Equity NA 0 -4 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 349 361 554 394
Total Liabilities & Shareholder's Equity NA 499 514 677 573
Total Common Equity 0 349 361 554 394
Shares Outstanding 82.50 81.60 68.70 68.40 62.60
Book Value Per Share 0.00 4.28 5.25 8.09 6.29

Fiscal Year End for Editas Medicine, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023
Assets          
Cash & Equivalents -99,999 265 279 296 323
Receivables NA 0 0 0 10
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 6 7 9 8
Total Current Assets NA 271 286 306 341
Net Property & Equipment NA 15 14 13 12
Investments & Advances NA 0 39 81 104
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 5 8 9 9
Total Assets NA 328 385 440 499
Liabilities & Shareholders Equity 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 12 14 8 8
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 29 28 31 35
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 15 15 15 8
Total Current Liabilities NA 72 74 66 63
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 54 54 54 61
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 4 3 2
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 152 153 146 150
Shareholders Equity 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,598 1,593 1,588 1,580
Retained Earnings NA -1,423 -1,361 -1,293 -1,231
Other Equity NA 1 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 176 232 294 349
Total Liabilities & Shareholder's Equity NA 328 385 440 499
Total Common Equity 0 176 232 294 349
Shares Outstanding 82.50 82.50 82.20 82.20 81.60
Book Value Per Share 0.00 2.13 2.82 3.58 4.28